Get started

Alpine Immune Sciences, Inc

No trades
See on Supercharts
Overview
News Ideas Financials Technicals Forecast

ALPN chart

Key stats

Market capitalization
474.862MUSD
Dividends yield (FY)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−1.71USD

About Alpine Immune Sciences, Inc

Sector
Health Technology
Industry
Biotechnology
CEO
Mitchell H. Gold
Website
alpineimmunesciences.com
Headquarters
Seattle
Employees
126
Founded
2007
ISIN
US02083G1004

Alpine Immune Sciences, Inc. is a development-stage pharmaceutical company, which engages in the discovery of protein-based immunotherapies to treat cancer and autoimmune and inflammatory diseases. Its product pipeline includes inflammatory diseases, immuno-oncology, and engineered cellular therapies. The company was founded in March 2007 and is headquartered in Seattle, WA.

Ideas

Biotechs To Watch This Week (FDA Hype Edition)My biotech watchlist for this week: FDA Hype $GLYC $AGEN $GLSI $ONCY $MTEM $ALPN $ALPN $CMPI $ATXI Potential Swings $CTXR $UBX $ZLAB Like and follow for weekly bio watchlists :) Also please comment your favorite tickers; I would love to hear what you guys think. Happy Trading!
0
5
$ALPNEntry price : 13.27 Fundamentals : - Sector: Medical - Biotech - EPS % Chg (Last Qtr): 55% - EPS % Chg (Previous Qtr): 17% - 3 Year EPS Growth Rate: 0% - EPS Est % Chg (Current Yr): 0% - Sales % Chg (Last Qtr): 592% - Sales % Chg (Previous Qtr): 21% - 3-Year Sales Growth Rate: 28% - Annua
Long
2
$ALPN confluence of supportSimilar to my recent SGMO idea, my view is that aVWAP support, 50% retracement and 50 day EMA support make a strong case that a relative low is in and higher prices are soon to come. For ALPN, the aVWAP cluster from recent significant lows/highs all cluster in a tight range in the mid 11s, which is
Long
Option and License AgreementAlpine Immune Sciences and AbbVie Announce Option and License Agreement for the Development and Commercialization of ALPN-101 Alpine Immune Sciences grants AbbVie option to license worldwide rights to ALPN-101, a phase 2-ready, first-in-class dual CD28/ICOS costimulation antagonist, building on Abb
Watching $ALPN --> $4.20 TargetFirst off, please don't take anything I say seriously or as financial advice. As always, this is on opinion based basis. That being said, given the current Alpine price, analyst have been giving it a strong buy rating and it looks like it is having a retracement of around early 2020 price. I think a
$ALPN Upside Targets Alpine Immune Sciences, Inc. is a development-stage pharmaceutical company. The firm engages in the discovering of protein-based immunotherapies therapies targeting the immune synapse to treat cancer, autoimmune, and inflammatory disorders. It offers Immunotherapy, Immune Synapse, vIgD Platform Tech
Long
Alpine Immune Science Inc on Breakout watch $alpnTechnically setting up for breakout. 200ma may be break. Downtrend approaching. RSI just crossed mid point. MACD reversing off Zero line as Histogram ticks higher Average analysts price target $11 ! Buy Company profile Alpine Immune Sciences, Inc. is a development-stage pharmaceutical company. The
Long
2
ALPN - One Target Hit. Going Again.Alpine Immune Sciences, Inc. is a development-stage pharmaceutical company, which engages in the discovering of protein-based immunotherapies therapies targeting the immune synapse to treat cancer, autoimmune, and inflammatory disorders. It offers Immunotherapy, Immune Synapse, vIgD Platform Technol
Long
ALPN - Starting To Clawback April Losses - Analyst's Bullish Alpine Immune Sciences, Inc., formerly Nivalis Therapeutics, Inc., is focused on developing a protein-based immunotherapies using Variant immunoglobulin domain (vlgD) platform technology. The vlgD platform is designed to interact with multiple targets, including many present in the immune synapse. T
Long

See all ideas 

News Flow

Keep readingKeep reading

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating

An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Be warned
This info isn't a recommendation for what you should personally do, so please don't take the data as investment advice. As with any trade, always look first, then leap. Read more in the Terms of Use.

Financials

Past performance
Revenue to profit conversion
Total revenue
Gross profit
EBITDA
EBIT
Net income
‪0%‬
‪0%‬
‪0%‬
‪0%‬
‪0%‬
Debt level and coverage
Earnings
Next:—
‪0‬

Brokers

TradeStation
TradeStation
Featured
Stocks, Crypto, Futures
4.44Fabulous
Learn more
OANDA
OANDA
Forex
4.53Great
Learn more
FOREX.com
FOREX.com
Forex
4.38Fabulous
Learn more
Interactive Brokers
Interactive Brokers
Stocks, Futures, Bonds
4.35Fabulous
Learn more

See all brokers 

Gain new superpowers

Take your analysis to the next level with our full suite of features, known and used by millions throughout the trading world.Learn more